COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants (NEOBRAIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00544895
Recruitment Status : Completed
First Posted : October 16, 2007
Last Update Posted : June 23, 2011
European Commission
Information provided by:
Hannover Medical School

Brief Summary:
NEOBRAIN brings together small and medium sized enterprises (SMEs), industry and academic groups devoted to the diagnosis, management, and neuroprotection in newborns with perinatal brain damage. The focus of NEOBRAIN is to identify strategies prevention of brain damage mainly observed in preterm newborns. (Copy from

Condition or disease
Brain Damage, Chronic

Layout table for study information
Study Type : Observational
Estimated Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants
Study Start Date : October 2007
Actual Study Completion Date : October 2010

Primary Outcome Measures :
  1. Brain white matter damage (WMD, defined by MRI ,US, EEG) [ Time Frame: during stay in NICU and until discharge ]

Secondary Outcome Measures :
  1. Developmental assessment [ Time Frame: at 2 years of age ]

Biospecimen Retention:   Samples With DNA
whole blood, urine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Preterm newborns with a gestational age < 28wks

Inclusion Criteria:

  • Gestational age < 28 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00544895

Layout table for location information
Medizinische Universität Innsbruck
Innsbruck, Austria, 6020
Hôpital Robert Debré
Paris, France, F-75019
Charité, Campus Virchow Klinikum
Berlin, Germany, 13353
Universität Duisburg-Essen
Essen, Germany, 45122
Hannover Medical School
Hannover, Germany, 30625
Fondazione I.R.C.C.S Ospedale Maggiore Policlinico MA.RE.
Milano, Italy
Azienda Ospedaliera Universitaria Senese
Siena, Italy, 53100
Wilhelmina Children's Hospital
Utrecht, Netherlands, 3508 AB
Perinatal Center
Gothenburg, Sweden, 41685
University Hospital
Lund, Sweden, 22185
Academic Children's Hospital
Uppsala, Sweden, 75185
Hôpital des Enfants
Geneva, Switzerland, 1211
Sponsors and Collaborators
Hannover Medical School
European Commission
Layout table for investigator information
Study Director: Olaf Dammann Medical School Hannover
Layout table for additonal information
Responsible Party: Prof. Dr. med. Olaf Dammann, Perinatal Infectious Disease Epidemiology Unit - Medical School Hannover Identifier: NCT00544895    
Other Study ID Numbers: LSHM-CT-2006-036534
First Posted: October 16, 2007    Key Record Dates
Last Update Posted: June 23, 2011
Last Verified: June 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Injuries
Brain Damage, Chronic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries